Xencor: J&J's Janssen Termintates Rights to Plamotamab
By Colin Kellaher
Xencor on Thursday said Johnson & Johnson's Janssen unit has terminated its rights to the tumor-targeted antibody plamotamab under a collaboration and license agreement the companies inked in 2021.
Xencor said it will regain exclusive worldwide rights to plamotamab, which the Pasadena, Calif., clinical-stage biopharmaceutical company has advanced through Phase 1 clinical development in hematologic cancers.
Xencor said its CD28 bispecific antibody platform remains the subject of two collaborations with Janssen, JNJ-9401 and JNJ-1493, which the J&J unit is developing in prostate cancer and B-cell malignancies, respectively.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 13, 2024 08:44 ET (12:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations